argenx
Manufacturing · Netherlands · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Laarderhoogtweg 25, Amsterdam, North Hol...Phone Number
+31107038441Website
www.argenx.comRevenue
$4.7 BillionStock Symbol
ARGXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About argenx
Argenx SE is a global immunology biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn blocker, is approved in 30+ countries for generalized myasthenia gravis, CIDP, and ITP, generating $4.2B in 2025 sales. The pipeline includes empasiprubart (complement inhibitor) and adimanebart (MuSK agonist), advancing toward "Vision 2030": 50,000 patients treated, 10 labeled indications.Explore more
argenx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is argenx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
argenx, which may be a good buyer, showed buying intent in Masked Content Topic
Check if argenx has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on argenx recently announced quarterly report
Check out if argenx is spiking on competitors!
Product Launch: Get notified when argenx launches new products
Website visits: Recent activity has been detected on your website
Click to see if argenx had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once argenx has new funding data
Congratulate Masked Content for being promoted to Masked Content at argenx
Recommended Actions
Find VP level buyers at argenx
Find more new buyers
Company Profile Activity
Activity Insights
argenx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
argenx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about argenx.
argenx financials insights
Gather financial insights about argenx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$54.4M
2017
Stock Offering
$100M
2020
Stock Offering
$750M
argenx Tech Stack
A closer look at the technologies used by argenx
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Argenx has reported product net sales of $1.5 billion for Q2, reflecting 60% year-over-year growth and 17% quarter-over-quarter growth, with US sales of $1.3 billion, Japan sales of $102 million, rest-of-world sales of $136 million, and $5 million related to product supply to XiLab in China.
Earnings, Finance
Project
Argenx has announced that its first registrational readout for Empasipre-bard in multifocal motor neuropathy (MMN) is expected later this year, supported by the efficacy, durability, and safety profile observed in the Phase 2 ARDA study, including sustained improvements in grip strength observed in open-label extensions.
Medical Research, Pharmaceuticals
Project
Argenx has announced preparations for a potential launch in autoimmune myositis, including active engagement with 650 rheumatologists treating the condition, disease state education initiatives, patient community engagement, and plans to expand its field force footprint in rheumatology.
Product Launch, Sales
Earnings
Earnings, Spending/Investment, Research & Development, Clinical Operations, Finance
argenx News & Media
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
This biotech leader continues to rack up clinical successes.Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.argenx to Present at Upcoming Investor Conferences
May 27, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding argenx
Sign Up For FreeTo access detailed company insights
Argenx SE is a global immunology biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn blocker, is approved in 30+ countries for generalized myasthenia gravis, CIDP, and ITP, generating $4.2B in 2025 sales. The pipeline includes empasiprubart (complement inhib... Read More
